Back to search
FDAFDA · Food and drugs·Recall number D-1362-2022

Divalproex Sodium Extended Release Tablets, USP, 250 mg, packaged in 100-count bottle, Rx only, Manufactured by: Amneal Pharmaceuticals, India, Distributed by: Amneal Pharmaceuticals, Bridgewater, NJ, NDC 65162-755-10

Published August 31, 2022 · Recall initiated: July 27, 2022

Summary

FDA records drug Class II recall D-1362-2022, published August 31, 2022 and initiated July 27, 2022. Recalling firm: Amneal Pharmaceuticals of New York, LLC; Status: Terminated; Reported quantity: 4,309 bottles; Lot: Lot #: AR210705, Exp 04/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed dissolution specifications.

What to do

Voluntary: Firm initiated · Letter

Get an email if DIVALPROEX SODIUM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DIVALPROEX SODIUM
Manufacturer
Amneal Pharmaceuticals of New York, LLC
Distributor
USA nationwide
UPC
0365162755107
Lot
Lot #: AR210705, Exp 04/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Divalproex Sodium Extended Release Tablets, USP, 250 mg, packaged in 100-count bottle, Rx only, Manufactured by: Amneal Pharmaceuticals, India, Distributed by: Amneal Pharmaceuticals, Bridgewater, NJ, NDC 65162-755-10 recalled?

Yes. FDA published recall D-1362-2022 on August 31, 2022. Reported hazard: Failed dissolution specifications.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DIVALPROEX SODIUM. UPC: 0365162755107.